Essex Bio-Technology (HK:1061) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Essex Bio-Technology Limited has announced that its subsidiary has received approval to commercialize its preservative-free unit-dose Sodium Hyaluronate Eye Drops (0.3%) in the People’s Republic of China. The product is designed to treat a variety of ocular diseases and symptoms, providing a new preservative-free treatment option for conditions like dry eye syndrome. This marks a significant step for the company in expanding its portfolio of ophthalmic products in the Chinese market.
For further insights into HK:1061 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue